MX2023000919A - Inhibidores de factores del complemento y usos de los mismos. - Google Patents

Inhibidores de factores del complemento y usos de los mismos.

Info

Publication number
MX2023000919A
MX2023000919A MX2023000919A MX2023000919A MX2023000919A MX 2023000919 A MX2023000919 A MX 2023000919A MX 2023000919 A MX2023000919 A MX 2023000919A MX 2023000919 A MX2023000919 A MX 2023000919A MX 2023000919 A MX2023000919 A MX 2023000919A
Authority
MX
Mexico
Prior art keywords
inhibitors
disclosed
complement factors
disease
compounds
Prior art date
Application number
MX2023000919A
Other languages
English (en)
Inventor
Claudia Beato
Dean R Artis
Colin Philip Leslie
Luca Biagio Mileo
Federico Sorana
GUGLIELMO Bruno DI
Chiara Padroni
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of MX2023000919A publication Critical patent/MX2023000919A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan compuestos de fórmula I y II y sales farmacéuticamente aceptables de los mismos. También se divulgan métodos para tratar un trastorno neurodegenerativo, una enfermedad inflamatoria, una enfermedad autoinmunitaria, una enfermedad oftalmológica o un trastorno metabólico usando los compuestos divulgados en el presente documento.
MX2023000919A 2020-07-20 2021-07-19 Inhibidores de factores del complemento y usos de los mismos. MX2023000919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063054064P 2020-07-20 2020-07-20
PCT/US2021/042198 WO2022020244A1 (en) 2020-07-20 2021-07-19 Inhibitors of complement factors and uses thereof

Publications (1)

Publication Number Publication Date
MX2023000919A true MX2023000919A (es) 2023-04-19

Family

ID=79729495

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000919A MX2023000919A (es) 2020-07-20 2021-07-19 Inhibidores de factores del complemento y usos de los mismos.

Country Status (17)

Country Link
US (2) US11814404B2 (es)
EP (1) EP4185592A1 (es)
JP (1) JP2023534974A (es)
KR (1) KR20230041758A (es)
CN (2) CN116947903A (es)
AR (1) AR123011A1 (es)
AU (1) AU2021311455A1 (es)
BR (1) BR112023001007A2 (es)
CA (1) CA3186022A1 (es)
CL (1) CL2023000191A1 (es)
CO (1) CO2023000683A2 (es)
IL (1) IL299840A (es)
MX (1) MX2023000919A (es)
PE (1) PE20231435A1 (es)
TW (1) TW202216168A (es)
UY (1) UY39331A (es)
WO (1) WO2022020244A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65572C2 (en) 1997-04-24 2004-04-15 Ortho Mcneil Pharm Inc Substituted imidazoles, intermediate compounds for the preparation thereof, a method for the preparation of substituted imidazoles and a method for the treatment of inflammatory diseases
JP5120957B2 (ja) * 2006-01-13 2013-01-16 エルジー・ケム・リミテッド 発光物質およびこれを用いた有機発光素子
US8221907B2 (en) 2007-07-07 2012-07-17 Idemitsu Kosan Co., Ltd. Chrysene derivative and organic electroluminescent device using the same
WO2015003146A1 (en) * 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
KR101635154B1 (ko) * 2014-08-28 2016-06-30 (주)더블유에스 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자
KR102233296B1 (ko) * 2014-11-18 2021-03-29 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AR103397A1 (es) * 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
US10111885B2 (en) * 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR101981245B1 (ko) 2015-10-27 2019-05-22 주식회사 엘지화학 고리 화합물 및 이를 포함하는 유기 발광 소자
KR101806464B1 (ko) 2015-11-19 2017-12-07 (주)랩토 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자
KR102238925B1 (ko) * 2018-06-11 2021-04-12 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2020032428A1 (ko) * 2018-08-09 2020-02-13 덕산네오룩스 주식회사 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치
CN109574910B (zh) * 2018-12-19 2021-07-02 山西大学 一种咔唑衍生物mcab及其制备方法和应用
CN111087387B (zh) 2019-12-26 2022-04-29 厦门天马微电子有限公司 一种有机化合物、显示面板及显示装置
CN111423390A (zh) 2020-03-30 2020-07-17 北京燕化集联光电技术有限公司 一种新型结构化合物及其应用
CN111662309B (zh) 2020-07-10 2021-11-09 北京燕化集联光电技术有限公司 一种多杂环结构化合物及其应用
CN113045585A (zh) 2021-03-16 2021-06-29 吉林奥来德光电材料股份有限公司 一种有机稠环化合物及其制备方法和应用

Also Published As

Publication number Publication date
IL299840A (en) 2023-03-01
CL2023000191A1 (es) 2023-09-08
CN116261564A (zh) 2023-06-13
EP4185592A1 (en) 2023-05-31
UY39331A (es) 2022-02-25
US11814404B2 (en) 2023-11-14
PE20231435A1 (es) 2023-09-14
WO2022020244A1 (en) 2022-01-27
US20240109920A1 (en) 2024-04-04
CA3186022A1 (en) 2022-01-27
CO2023000683A2 (es) 2023-01-26
BR112023001007A2 (pt) 2023-03-28
TW202216168A (zh) 2022-05-01
AR123011A1 (es) 2022-10-19
KR20230041758A (ko) 2023-03-24
US20220048930A1 (en) 2022-02-17
JP2023534974A (ja) 2023-08-15
AU2021311455A1 (en) 2023-02-16
CN116947903A (zh) 2023-10-27

Similar Documents

Publication Publication Date Title
AU2024202573A1 (en) KRas G12C inhibitors
GEP20237568B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
PH12018501920A1 (en) Bromodomain inhibitors
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
WO2017127430A8 (en) Irak4 inhibiting agents
DE602007014186D1 (de) Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer
MX2021006695A (es) Moduladores de trex1.
JO3789B1 (ar) التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MY190748A (en) Tricyclic sulfones as ror? modulators
EA202193015A1 (ru) Ингибиторы cdk
MX2023001071A (es) Tratamiento de la migraña.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
MX2020012980A (es) Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.
MX2022007626A (es) Combinaciones.
PH12019501566A1 (en) Amide compounds and use thereof
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2023000919A (es) Inhibidores de factores del complemento y usos de los mismos.
EA201991128A1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
MX2021012824A (es) Métodos para tratar el prurito.
MX2020013352A (es) Tratamiento para migrañas.
MX2021007258A (es) Composiciones de esparsentan amorfas.